Biotech Exit Strategy Of Choice Is Acquisition, Not IPO, Investor Says
Executive Summary
Venture capital firms are increasingly shaping biotech companies to look like acquisition prospects from the outset, rather than candidates for initial public offerings, according to one investor's analysis